Solas BioVentures
Solas BioVentures is a Chattanooga, Tennessee-based early-stage venture capital firm that invests exclusively in biopharmaceuticals, medical devices, and digital health through multiple fund vehicles as an SEC registered investment adviser.
- Company typePrivate
- Founded2014
- HeadquartersChattanooga, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Solas BioVentures does
Solas BioVentures is an early-stage venture capital firm headquartered in Chattanooga, Tennessee, that invests exclusively in the life sciences sector, spanning biopharmaceuticals, medical devices, and digital health. Founded in 2014 by David Adair, MD/MBA, Mark Hackett, JD, and Michael Hoey, the firm operates as an SEC registered investment adviser under the legal entity Solas BioVentures Management, LLC and maintains a satellite office in Research Triangle Park, North Carolina. Its investment vehicles include Fund I, Fund II, an Emerging Healthcare Fund, and Solas Sidecars/Management Team SPVs, distributed exclusively through direct Limited Partner relationships and supported by a Juniper Square investor portal.
The firm applies a founder-centric investment philosophy, with a team combining physicians (David Adair in Maternal-Fetal Medicine, Travis Manasco triple-board certified in Emergency/Critical Care/Neurocritical Care), PhD scientists, attorneys (Mark Hackett), and operators/advisors with experience at Eli Lilly, IQVIA/Quintiles, and Philips Ventures. Co-founder Michael Hoey brings an inventor track record of 200+ patents and eight founded medical products companies that collectively raised $400M and produced $1.5B+ in combined exits. Active portfolio companies include Francis Medical ($80M Series C in January 2025), Basking Biosciences ($27.5M tranche unlocked in October 2025), Cryosa, IO Urology, Vektor Medical, Intershunt Technologies, and Dimension Bio. Realized exits include Nxthera (acquired by Boston Scientific for $400M), Aegea Medical (acquired by CooperSurgical), and Knopp Biosciences (acquired by Biohaven).
The business model follows standard venture capital economics: Solas raises capital from Limited Partners into successive fund vehicles, deploys that capital into early-stage life science companies, charges management fees on committed/invested capital, and earns carried interest on profitable exits. Distribution is direct-relationship driven with no public marketing channels beyond a LinkedIn presence, company website, and newsletter. The firm does not publicly disclose revenue, fund sizes, or AUM.
Solas BioVentures firmographics
Firmographics- Name
- Solas BioVentures
- Legal name
- Solas BioVentures Management, LLC
- Website
- https://solasbio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Solas BioVentures is a Chattanooga, Tennessee-based early-stage venture capital firm that invests exclusively in biopharmaceuticals, medical devices, and digital health through multiple fund vehicles as an SEC registered investment adviser.
- Ownership category
- akta.pro rank
Solas BioVentures industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Micro-VC & Angel Funds (FSANAAAI)
Keywords
Where Solas BioVentures is headquartered
LocationHeadquarters
- HQ city
- Chattanooga
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Solas BioVentures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Distribution channels1 record
Marketing channels2 records
Solas BioVentures product offering
Product offeringCore offering
Solas BioVentures is an early-stage venture capital firm that invests exclusively in life sciences—biopharmaceuticals, medical devices, and digital health companies. The firm manages multiple investment vehicles (Fund I, Fund II, an Emerging Healthcare Fund, and Solas Sidecars & Management Team SPVs) and provides capital plus strategic guidance to portfolio company founders. Investors (Limited Partners) access portfolio reporting and fund information through the Juniper Square investor portal.
Product overview
Solas BioVentures is an early-stage venture capital firm that operates multiple investment fund vehicles rather than a unified product platform. The firm's investment offerings include the Emerging Healthcare Fund (flagship fund), Fund II, Fund I, and Solas Sidecars & Management Team SPVs for co-investment opportunities. The firm also provides investor relations services through the Juniper Square portal, enabling limited partners to access portfolio data and investment documentation. The investment strategy focuses exclusively on biopharmaceuticals, medical devices, and digital health companies, with a portfolio spanning multiple funds including both active investments and exited companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Emerging Healthcare Fund Solas BioVentures' flagship early-stage investment vehicle focused on biopharmaceuticals, medical devices, and digital health companies. Available to Limited Partners as a fund commitment.
- Fund II Second-generation investment fund continuing Solas BioVentures' strategy of investing in early-stage life science companies. Available to Limited Partners as a fund commitment.
- Fund I Solas BioVentures' original investment fund establishing the firm's early-stage life science investment strategy. Available to Limited Partners as a fund commitment.
- Solas Sidecars & Management Team SPVs Special purpose vehicles used for co-investment opportunities alongside the main funds, allowing for flexible investment structures. Available to Limited Partners as co-investment commitments.
- Juniper Square Investor Portal Web-based investor relations portal enabling Limited Partners to access portfolio information, performance data, and investment documents securely.
Companies that use Solas BioVentures
Customer profileSegments1 record
Ideal customer profiles2 records
Solas BioVentures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Solas BioVentures partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Juniper SquarecoreInvestor portal platform used by Solas BioVentures for LP relationship management and investment reporting
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Solas BioVentures competitors and assessment
Company assessmentDirect peers
- Atlas Venture: Early-stage venture capital firm focused on building biotech companies from inception. Atlas Venture's stage focus, sector specialization in life sciences, and founder-centric model closely mirror Solas BioVentures' approach.
- 5AM Ventures: Early-stage life sciences venture capital firm investing in biopharmaceuticals, medical devices, and research instruments. 5AM's fund structure, sector concentration, and stage focus are highly comparable to Solas BioVentures.
- Frazier Healthcare Partners: Healthcare-dedicated venture capital firm investing across biopharma and medtech stages. Frazier's Life Sciences strategy closely parallels Solas BioVentures' sector mandate and early-stage orientation.
- Longitude Capital: Healthcare-focused venture capital firm investing in growth-stage biopharmaceuticals and medical technologies. Longitude's sector mandate and fund structure are comparable to Solas BioVentures.
- SV Health Investors: Healthcare and biotech-focused venture capital firm with deep life sciences expertise. SV Health's biotech strategy and stage orientation closely align with Solas BioVentures' investment approach.
Broad incumbents
- ARCH Venture Partners: One of the largest and most established early-stage biotech VCs, founded to commercialize academic research. ARCH operates at a much larger scale than Solas but shares the early-stage life sciences focus.
- Polaris Partners: Multi-stage venture firm with a dedicated life sciences practice investing in biotech and medical technology. Polaris's healthcare team overlaps directly with Solas BioVentures' investment focus.
- OrbiMed: Healthcare-dedicated investment firm across private equity, venture, and royalty opportunities. OrbiMed's venture practice competes for similar biopharma and medtech deals as Solas BioVentures.
- RA Capital Management: Healthcare-focused investment manager with dedicated biotech venture activity. RA Capital's biotech crossover and early-stage investing intersects with Solas BioVentures' deal universe.
Regional players
- Forbion: European life sciences venture capital firm investing in biotech and medtech. Forbion competes for similar therapeutic opportunities to Solas BioVentures but primarily from a European base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Solas BioVentures social profiles
Digital presenceSolas BioVentures compliance and trust
Trust signalCompliance1 record
Solas BioVentures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Solas BioVentures leadership team
Management profileNumber of profiles
Profiles13 records
Solas BioVentures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Solas BioVentures M&A and investment
M&A and investmentM&A
Investments22 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Solas BioVentures
What does Solas BioVentures do?
Solas BioVentures is an early-stage venture capital firm that invests exclusively in life sciences—biopharmaceuticals, medical devices, and digital health companies. The firm manages multiple investment vehicles (Fund I, Fund II, an Emerging Healthcare Fund, and Solas Sidecars & Management Team SPVs) and provides capital plus strategic guidance to portfolio company founders. Investors (Limited Partners) access portfolio reporting and fund information through the Juniper Square investor portal.
Is Solas BioVentures a public or private company?
Solas BioVentures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Solas BioVentures founded?
Solas BioVentures was founded in 2014. It employs 11 to 50 people.
Where is Solas BioVentures based?
Solas BioVentures is headquartered in Chattanooga, United States, in the North America region.
Who are Solas BioVentures's main competitors?
Direct peers on record are Atlas Venture, 5AM Ventures, Frazier Healthcare Partners, Longitude Capital and SV Health Investors. Broad incumbents are ARCH Venture Partners, Polaris Partners, OrbiMed and RA Capital Management. Forbion is listed as a regional player.
Does Solas BioVentures have an API?
No public API is recorded for Solas BioVentures.
What industry is Solas BioVentures in?
Solas BioVentures's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAI, Micro-VC & Angel Funds. Its NAICS code is 523940 and its SIC code is 6282.